Apr 18, 2023 / 12:00PM GMT
Operator
Ladies and gentlemen, thank you for standing by. Welcome to Gamida Cell conference call for the FDA approval of Omisirge. My name is Michelle, and I will be your operator for today's call. Please be advised that this call is being recorded at Gamida Cell request.
I would like to introduce your host for today's conference, Mike Kuczkowski of Gamida Cell, Corporate Communications. Please go ahead.
Mike Kuczkowski - Orangefiery - IR
Thank you, Michelle, and good morning, everyone. With me on our call today are Abbey Jenkins, President and Chief Executive Officer; Ronit Simantov, Chief Medical Officer and Scientific Officer; Michele Korfin, Chief Operating Officer and Chief Commercial Officer; and Shai Lankry, Chief Financial Officer.
Before we begin, I want to remind everyone that during this call, we may make forward-looking statements about our future expectations and plans including with respect to the timing and initiation of and progress of and data reported from the preclinical and clinical trials of our product, Omisirge, and our product
Gamida Cell Ltd Omisirge Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot